Corante

About this Author
Derek Lowe
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Pharma Blogs:
The Science Business
Org Prep Daily
Kilomentor
On Pharma
Kinase Pro
Chemical Quantum Images
The LouRoe
One in Ten Thousand
Periodic Tabloid
Chemical Musings
C&E News Blog
Chemiotics II
Noel O'Blog
In Vivo Blog
Chirality
BBSRC/Douglas Kell
Drug Discovery Opinion
The Chemblog
Realizations in Biostatistics
Heterocyclic Chemistry Blog
Molecule of the Day
Chemjobber
WSJ Health Blog
PK/PD
Social Detritus
ChemSpider Blog
Node in the Noosphere
Pharmagossip
Organometallic Current
Useful Chemistry
Great Molecular Crapshoot
No Name No Slogan
Post Doc Ergo Propter Doc
SimBioSys
Culture of Chemistry
The Curious Wavefunction
Chemical Sabbatical
Totally Synthetic
Molecular Philosophy
Zusammen
Pharma's Cutting Edge
My Chemical Journey
The F- Blog
Chemical Professionals
Generally Chemistry
Chemistry World Blog
Eigenfunction/Eigenvalue
Synthesizing Ideas
Carbon-Based Curiosities
Business|Bytes|Genes|Molecules
Eye on FDA
Sigma-Aldrich ChemBlogs
Peter Murray-Rust
Chemical Forums
Depth-First
Curly Arrow
ChemCafe
Power of Goo
Fetz the Chemist
Carbon Tet
Chemical Crosspatch
Sceptical Chymist
Atomchuxky
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa
Making Graphite Work
Realm of Organic Synthesis
Liquid Carbon
Pharma Blog Review


Science Blogs and News:
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Life of a Lab Rat
Nobel Intent
SciTech Daily
Is This Thing On?
Science Blog
Eastern Blot
FuturePundit
Flags and Lollipops
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Terra Sigillata
Transterrestrial Musings
Slashdot Science
A Scientist's Life
Living the Scientific Life
Humans in Science
Speculist
Science, Shrimp and Grits
Cosmic Variance
The Capsule
Zeroth Order Approximation
Science Library Blog
Biology News Net


Medical Blogs
Med Tech Sentinel
DB's Medical Rants
Science-Based Medicine
GruntDoc
The Health Care Blog
Respectful Insolence
Black Triangle
Diabetes Mine


Economics and Business
Marginal Revolution
Arnold Kling
The Volokh Conspiracy
Knowledge Problem
The Stalwart


Politics / Current Events
Virginia Postrel
Tinkerty Tonk
Instapundit
Megan McArdle
Mickey Kaus
Colby Cosh
Alien Corn
No Watermelons


Belles Lettres
Two Blowhards
Critical Mass
Arts and Letters Daily
God of the Machine
Armavirumque
About Last Night
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« The Inscrutable French | Main | Forty NMR Magnets and 3000 Proteins Later. . . »

October 9, 2006

Here and There

Email This Entry

Posted by Derek

A few miscellaneous notes this morning: I had an e-mail from a reader who asks "Why is Imclone stock worth anything at all?" He was referring to the competition they're now facing from Amgen, and the managerial turmoil that's been going on for months now. For my part, I think that IMCL is worth something, but I sure don't think it's worth $29.44/share, which is where I went short on Friday. (In the future, if I write about them, I'll make note of that fact each time in the interest of disclosure). I realize that this puts me on the other side of the fence from Carl Icahn, a person whose stock-picking judgment I might normally defer to. But in this case, I think I may know more about cancer therapies than Icahn does. We'll find out.

On an unrelated topic, I have a request. Does anyone know of a commercial source for a library of diverse phenyl carbamates? I realize that that's not the usual sort of diversity library - if I were after secondary amines, the offers just wouldn't stop. I can find scattered examples from various suppliers, but if someone had a bunch already collected, it would be a great time-saver. Any ideas?

But finally, though, physics is more on my mind than chemistry this morning. I'm digesting the unpleasant implications of this map, courtesy of the US Geological Survey. . .

Comments (2) + TrackBacks (0) | Category: Cancer | Current Events


COMMENTS

1. Ashutosh on October 9, 2006 3:51 PM writes...

Well, sooner or later, many countries like Iran and N Korea are going to conduct tests. One of the viewpoints in this scenario is that of Kenneth Waltz, who favours actually letting all countries have some nukes for deterrence. So give the N Koreans some nukes, and tell them to then adhere to strict international standards enforced universally. I agree that if done the right way, nuclear 'proliferation' may actually decrease the risk of nuclear conflict. The late Hans Bethe who was involved in arms control throughout the cold war also said that an ideal scenario would be one in which there are a few hundred weapons, 'some in the east, some in the west, and some in the middle'

This post has been published twice by the way :)

Permalink to Comment

2. Chrispy on October 9, 2006 6:58 PM writes...


I still want to know who offered $36/share for them. You'd have to be nuts!

Good for you for shorting; I'll be interested to hear how it turns out!

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Dealing With Hedgehog Screening Results
Animal Rights, You Say?
Blogroll Update
Pharma's Return on Investment: Yikes
How A Real Drug Industry Project Meeting Goes
Ghostwriting
Just Give It to NIH
How Not To Do It: The Secret Patent Decoder Ring